Objective To compare the clinical safety and efficacy of Temozolomide (TMZ) chemotherapy alone and temozolomide chemotherapy combined with Tumor Treating Fields (TTF) in the treatment of glioblastoma.Methods The literatures published in Pubmed, Cochrance, Embase, Ovid, Scopus, Web of science, CNKI, Wanfang Data, VIP Database for Chinese Technical Periodical, Chinese Biological Medical Datebase and Google Scholar Self-built Database up to April 5, 2020 were searched, and TMZ and TTF+TMZ were selected for a randomized controlled trial. According to the inclusion and exclusion criteria, the overall survival(OS) rate and progression free survival(PFS) rate were taken as the outcome indicators, and finally the Review Manager was used for statistical analysis.Results Four studies were included, including 1091 patients, including 381 cases in TMZ group and 710 cases in TTF+TMZ group. The mean OS(26.9 months) and mean PFS(14.7 months) of TTF+TMZ group were significantly better than those of TMZ group (12.63 months) and mean PFS(5 months) (P<0.01).Conclusions TTF+TMZ is more effective than TMZ alone in treating GBM.